George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
I don't think you understand it well enough.
People complain about no revenue but you want to ditch the lab. The evaluations will cost more and you cannot do additional work on it to increase the value or chances of success.
The company balance sheet which needs revenue to attract investment needs revenue and not just a deal unless you get huge payments.
I agree no more buy and build until a much higher share price. But we are at a stage where things will kick in. You will lose contacts that they would have built and slow things down. Believe me when I say you will get capitulated with dilutions with a new BOD.
It is pure fantasy to expect someone to walk in and buy 5% of the company. They need lots of time and money.
Viera, no I am down like most. If you go ahead with this we will get zero positive news and 201 regardless of your opinion will likely fail.
If you are not invested and or not fully invested then you can afford this drop. People have lost senses or lack the ability to think things through.
You have no experience that you can replace them with. It really is counterproductive at the moment.
IF you think you will invest with a new BOD then let me tell you will get diluted again and again because for them it is a fresh start and they will need lots of time and likely a change of strategy possibly to clinical stage work.
On the basis the merger is still proceeding. If it was dead then that would likely have already happened and legally they have to announce it. The 30 and 15 notice was for DD only and that I am assuming has passed. The letter of intent is still in place for EUDA. The chances are good for sure but not guaranteed.
But it can turn some decent hope is better than no hope. You then have notice periods, disgruntled BOD members whilst they leave and new ones that will come in fresh needing time and will need to keep raising money again and again. As I said you have no solutions it should be a last resort but we have not reached that point.
You don't have any sensible solutions. At this moment of time we are at an important stage. We do not need instability. This is not some power battle.
Once we get some outcomes then we can see. I did say the end of March at least for now to see if the merger completes.
If 201 completes then everything comes into play. Removing BOD now can have disastrous consequences.
You don't have any clue about the strategy all you know is 201, 301 and 401 and even that you have little to no clue.
Maybe if you worked you could invest more than 900 pounds which is probably worth nothing now.
The lab helps to develop the pre clinical projects and collaborations help to limit the risk and improve the results therefore increasing the value of any future deals. Also the lab will help generate revenue and it would allow investment to come in by improving revenue. Eventually.
Just my opinion.
These projects will be worth decent money but the hope is CLX will be big this year. The rest have the potential to add decent value which is why we can attract large investors. The lab revenue and balance sheet helps with that plus obviously 201 will be a deal maker for us.
Oncology is by far the most important area for dealmaking in the biopharma industry. The value of cancer deals for which financial details were disclosed reached $73.1 billion in 2021 and $93.1 billion in 20221. Here, we analyze the economics of disclosed partnering, licensing and acquisition deals in the oncology field from 2015 through 2022 (Box 1). The analysis provides pointers about the requirements to pursue a deal, the right timing, how to maximize deal value and how to adapt to the current challenging market.
Deal economics
Early dealmaking appears to be the norm in oncology nowadays, as 73% of non-acquisition deals from 2015 to 2022 involved preclinical ventures (Fig. 1).
Mean deal values by deal type and proportions of oncology deals by stage of development
Fig. 1 | Trends in oncology deals: 2015–2022. Mean deal values by deal type and proportions of oncology deals by stage of development. See Box 1 for details of the dataset and analysis.
Focusing on preclinical deals, for which sufficent data are available for analysis, the mean potential deal value of a preclinical acquisition ($359 million) was much lower than that for a preclinical licensing deal ($540 million) or partnering deal ($985 million) (Fig. 2). However, partnering or licensing deals were considerably more backloaded than acquisitions, as mean upfront payments for acquisitions ($130 million) were 2.5–4.2-fold higher. Biotechs and their backing investors likely prefer deals with upfront payments that provide good initial return on investments, rather than going for bigger deals that are mostly based on contingent milestone payments.
Indeed, based on our previously reported estimate for the invested capital in preclinical oncology ventures, an upfront payment of $130 million would return more than four times the typical invested capital2. Early exits are also preferred by most investors as their funds often have closed-end terms that are difficult to reconcile with long earn-out structures. Furthermore, early exits provide an early validation of a fund’s performance, greatly facilitating the raise of a next fund.
Not if you are investing.
Only the new compounds will attract the large pharma giants at the moment as it is mainly novel science with full patents.
201 can attract it at phase 3 but even at phase 2 it is worth decent money. At phase 3 you are looking at 201 being worth maybe 300-500 million. What matters is if they have funding and the right scientific skills which I am sure they do.
The 65 million milestones plus funding for trials plus revenue and upfront payment is where the value is for us at the moment as far as 201 is concerned. Then you got all the other projects like CLX potentially worth much more this year.
It doesn't matter. We are not looking for Warren Buffet investing here. We have our first institutional investor and more will come.
They have taken a large stake based on research and potential. That is all that matters. They will know more than we do.
The market cap was 0.5 million due to the situation at the time therefore to raise decent money at those low prices is next to impossible. They did well to only have 130 million now although it could have been lower.
Get some more new out ideally some lab revenue and focus on bringing one more institutional investor in and get the SP moving.
They would know nothing is factored in at this price. All the below would be very significant relative to our current price.
1) Outcomes of evaluation projects leading to SPV if successful
2) 201 deal conclusion
3) Several lab contracts
4) CLX update
5) 401 deal conclusion
We will get news on this positive or negative but most of this should be positive. They can see the potential from this low price.
The first is always the most difficult. More will come as they start to generate revenue or complete a deal and the share price will start moving.
I am particularly looking forward to the CLX update which is due early this year. A few decent lab contracts are highly likely very soon and 201 is still on. Great price to buy with very limited risk.
It's not easy to build a company from scratch so although I am down I give them some credit and feel that now with the foundations in place the share price will move forward at a decent pace.
The foundations are in place and I am sure we will also get some lab contracts which will attract investment given the value of the strategy. All Suzy needs to do is get another large investor buying in the open market and and this will fly.
The big ones are CLX and 201 and I think we will get news on that in the coming weeks. With a 5 million market cap and cash until 2025 I would fancy my chances of double digits at least.
I feel those buying here will do well over the coming months. The negative ones will just be buying at a much higher price. DYOR.
If you can get one then you can get more than one. Just needs a bit of lab revenue and maybe a CLX update then you can bring them in as Valirx has plenty of value on offer at this market cap.
201 would be a huge bonus but like Adam said we have about 5 projects including the lab that can really bring significant value hopefully in the coming weeks/months I would think.
The current SP should be at the bottom now with all this positive news and more to come.
Here is the ultimate lie and bullchit by AIM's biggest deramper Porky. You pick and choose what you want but the facts are below.
Porky's comment
The broker reports have proven accurate every time without exception for when the cash runway runs out. I have zero reason to suspect it will be any different now. Hence on current trajectory they will need to raise in September.
But from Turner Pope recent note:
Cash runway now appears sufficient to carry it well into 2025
Full year 2023E Group net losses along with the cost of establishing/facilitating Inaphaea Biolabs (including the
acquisition of Imagen Therapeutics), resulted in an average estimated cash burn of a little over £200,000/month for
the period. If one now prudently assumes further, albeit somewhat reduced, Group net losses for 2024E, during
which time it utilises the newly raised net funding to accelerate exploitation and integration of its acquired BioBank
materials in tandem with commercial development/brand establishment within Inaphaea while also advancing
its preclinical product pipeline in the absence of further cash acquisition(s), the Group now appears to have runway
sufficient to carry it into Q2 2025.
Between now and then, of course, various upside scenarios suggest this period could become significantly extended.
This could be derived through securing higher volumes of fee-paying service customers for Inaphaea, potential
signing of licensing agreements with external parties willing to pay upfront charges and fund ongoing
development of the Group’s preclinical and/or clinical assets which, in turn, could also attract continuing
milestones instalments. Any such outcome could be both transformative for ValiRx’s balance sheet while also
proving its business model.
Projected based on broker report Q2 FY2025. They will get some decent lab revenue over the year so maybe end of the year.
201 remains in place so the extra 2 million takes it to 2026.
At the end of the day all that matters is delivery. If the SP goes to where it should be then it is nothing.
At least try and understand the conversation Nick. You can't even do that because it was not me that said it.
You admitted yourself that you have minimal investment compared to the past. You can afford to buy if this crashed at our expense. If you don't believe in the company then why are you even here.
You and Porky are the last people that I would listen to.
Anyway pointless. Not going to argue with those that have agendas.
The merger should still be complete successfully given all the work that has been done so all these arguments are irrelevant. If they announce a LOI then it is ongoing unless an RNS says otherwise.
The only issue being lack of update but that is self inflicted by the BOD in my opinion as they should be feeling back to TRX so that EUDA releases an update.
Later for now. Waste of time as only the outcome of the merger is what matters and it is not priced in anyway.